PE 22-28
Seven-residue peptide derived from spadin, used in TREK-1 channel research.
Prepared to order · approx. 7 days + Royal Mail Tracked 24
SKU BP-PE2228-10 · ≥99% (see COA) · Lyophilised powder
PE 22-28 overview
PE 22-28 is a shortened analogue of spadin, a peptide derived from the sortilin propeptide. It is supplied as a lyophilised solid for in-vitro research.
PE 22-28 research background
Evidence status: Findings summarised here come from published cell-culture and animal research only; no controlled human studies were identified. They are not established effects in humans, have not been evaluated by the MHRA, and are provided for scientific context only. This product is supplied strictly for laboratory research and is not for human or veterinary use.
Established research
Peer-reviewed published findings, with referencesOverview & discovery history
Chemical identity
Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.
Mechanisms investigated
Research areas & model types
Human clinical research status
- No human studies were identified. It is not an approved medicine.
Safety observations reported in studies
- No dedicated safety studies were identified.
Known limitations
- The evidence is rodent-only and from one research consortium.
- The sequence must be confirmed from the COA.
Storage & handling for laboratory use
Store at −20 °C. Protect from light.
Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.
- Allow the sealed vial to reach room temperature before opening to limit condensation.
- Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
- Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.
Emerging & theoretical
Unconfirmed — hypotheses & ongoing researchThese are unconfirmed hypotheses and early-stage lines of enquiry, not established effects. Not evaluated by the MHRA. Not for human or veterinary use.
Hypotheses proposed by researchers
- Researchers have proposed TREK-1 blockers derived from spadin as a new concept for fast-acting antidepressant drug design, based on rodent data [3][1].
Open scientific questions
- How selective is it across K2P channels?
- Does it cross the blood–brain barrier?
Preprints: none included (no relevant preprint could be verified). Anecdotal, user-reported or social-media material is deliberately excluded.
References
- Mazella J, Pétrault O, Lucas G et al.. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol. 2010. PubMed 20405001 · doi:10.1371/journal.pbio.1000355
- Djillani A, Pietri M, Moreno S et al.. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol. 2017. PubMed 28955242 · doi:10.3389/fphar.2017.00643
- Djillani A, Pietri M, Mazella J et al.. Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin. Pharmacol Ther. 2019. PubMed 30291907 · doi:10.1016/j.pharmthera.2018.10.003
- Veyssiere J, Moha Ou Maati H, Mazella J et al.. Retroinverso analogs of spadin display increased antidepressant effects. Psychopharmacology (Berl). 2015. PubMed 25080852 · doi:10.1007/s00213-014-3683-2
Every reference was checked against PubMed (NCBI) before publication. Summaries describe published research only and are not claims of any effect in humans or animals.
Certificates of analysis
[No batch COA published yet. The certificate for each lot will be listed here and in the COA checker before release.]
Related research compounds
Browse similar compounds: Neuropeptide research peptides or the full catalogue.